NEW YORK (GenomeWeb) – Interpace Diagnostics today said that it has regained compliance with a Nasdaq listing requirement calling for at least $2.5 million in stockholder equity.

As a result, the company's shares will remain listed on the Nasdaq Capital Market.

The firm was notified in November that it failed to meet the listing requirement and faced delisting action. On April 10, though, it received a letter from Nasdaq saying it had regained compliance.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.